What is ImmunityBio, Inc.'s market cap?

ImmunityBio, Inc. (IBRX) has a market capitalization of $7.3B and trades on NASDAQ.

What is ImmunityBio, Inc.'s revenue and profitability?

ImmunityBio, Inc. generated $141.0M in trailing twelve-month revenue with a net loss of $854.5M, representing a net margin of -606.2%. Gross margin stands at 99.3%, with free cash flow of -$298.9M. These figures are based on the Q1 2026 filing.

Who are ImmunityBio, Inc.'s competitors?

ImmunityBio, Inc.'s key competitors include Gilead Sciences, Merck, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.

Who does ImmunityBio, Inc. partner with?

ImmunityBio, Inc.'s notable partners include Serum Institute of India, BeOne Medicines Ltd., 3M IPC, and others.

What subsidiaries does ImmunityBio, Inc. have?

ImmunityBio, Inc.'s subsidiaries include Altor BioScience, GlobeImmune, Inc., NantKwest.

Where is ImmunityBio, Inc. headquartered?

ImmunityBio, Inc. is headquartered in United States of America and employs approximately 628 people. It has been publicly traded since 2021.

ImmunityBio, Inc.

IBRX

Market cap

$7.32B+213%

Revenue$141.0M+352%

Net income-$854.5M-109%

Free cash flow-$298.9M+20.7%

EPS (diluted)-$0.85-46.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$44.2MBeat by $1.1M EPS-$0.09Miss by $0.01

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$49.7M

EPS estimate-$0.09

Financials

Q1 2026

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation & ratios

Valuation

See full

Market cap$7.32B+213%

Enterprise value$7.56B+201%

P/S51.9×+10.6×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Current ratio6.7×+4.4×

Segments

By segment

See full

Reportable Segment$44.2M+168%

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Merck & Co.$322.95B+53.0%

Gilead Sciences$162.05B+15.3%

Bristol-Myers Squibb$127.75B+32.1%

ImmunityBio, Inc.$7.3B+213%

Artiva Biotherapeutics, Inc.$501.4M+595%

AIM ImmunoTech$6.9M+26.0%

LIM

Liminatus Pharma, Inc. Class A Common Stock$6.9M-96.8%

By revenue growth

ImmunityBio, Inc.+352%

Johnson & Johnson+8.1%

Gilead Sciences+3.5%

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

By net margin

Gilead Sciences30.99%+10.2pp

Johnson & Johnson21.48%-3.5pp

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

Artiva Biotherapeutics, Inc.-79.28%—

ImmunityBio, Inc.-606.15%+704pp

Profile

ImmunityBio is a vertically integrated biotechnology company focused on developing next-generation immunotherapies that activate both the innate and adaptive immune systems to treat cancer and infectious diseases. The company's core value proposition centers on its Cancer BioShield platform, which utilizes cytokine fusion proteins, adenovirus-vectored vaccines, and natural killer (NK) cell therapies to induce durable immunological memory. Its lead product, ANKTIVA, is a first-in-class IL-15 superagonist designed to rescue lymphopenia and enhance the efficacy of standard-of-care treatments.

Competitive position

ImmunityBio is a pioneer in IL-15 superagonist technology, holding the first FDA approval for this class of therapy. It maintains a competitive edge through vertical integration of manufacturing and a multi-modal platform approach to immune system activation.

GeographiesUnited States, United Kingdom, European Union, Saudi Arabia

Customer segmentsHealthcare providers, Specialty pharmacies, Government health programs

Business modelR&D-driven drug development, Direct product sales, Licensing and collaborations

SuppliersThird-party contract manufacturing organizations (CMOs), Specialized laboratory equipment suppliers, Raw material and reagent providers, Academic and government research partners

CustomersSpecialty distributors, Specialty pharmacies, Urology and oncology clinics, Hospitals and infusion centers

CountryUnited States of America

Listed2021

Employees628.0

CEORichard Gerald Adcock

SectorHealthcare

IndustryBiotechnology

Websiteimmunitybio.com

FilingsSEC EDGAR

Ask your AI about ImmunityBio, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s market cap?: ImmunityBio, Inc. (IBRX) has a market capitalization of $7.3B and trades on NASDAQ.
What is ImmunityBio, Inc.'s revenue and profitability?: ImmunityBio, Inc. generated $141.0M in trailing twelve-month revenue with a net loss of $854.5M, representing a net margin of -606.2%. Gross margin stands at 99.3%, with free cash flow of -$298.9M. These figures are based on the Q1 2026 filing.
Who are ImmunityBio, Inc.'s competitors?: ImmunityBio, Inc.'s key competitors include Gilead Sciences, Merck, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
Who does ImmunityBio, Inc. partner with?: ImmunityBio, Inc.'s notable partners include Serum Institute of India, BeOne Medicines Ltd., 3M IPC, and others.
What subsidiaries does ImmunityBio, Inc. have?: ImmunityBio, Inc.'s subsidiaries include Altor BioScience, GlobeImmune, Inc., NantKwest.
Where is ImmunityBio, Inc. headquartered?: ImmunityBio, Inc. is headquartered in United States of America and employs approximately 628 people. It has been publicly traded since 2021.